High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy

Journal of Viral Hepatitis

Volumn 10, Issue 3, 2003, Pages 205-209

  Vrolijk, J M ^a   Bekkering, F C ^a   Brouwer, J T ^a   Hansen, B E ^a   Schalm, Solko W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chronic hepatitis C; Cirrhosis; Genotype 1; Induction dose; Interferon; Long term therapy; Non response; Ribavirin; Treatment

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; ASCITES; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DRUG DOSE REDUCTION; FATIGUE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOSPITALIZATION; HUMAN; INJECTION SITE; JAUNDICE; LIVER CIRRHOSIS; LIVER FAILURE; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; SIDE EFFECT; VIRUS LOAD; VISUAL IMPAIRMENT; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0037648523     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2003.00408.x     Document Type: Article

References (22)

1. National Institutes of Health Consensus Development. Conference Panel Statement: management of hepatitis C. Hepatology 1997; 26: 2S-10S.
2. EASL International Consensus. Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol 1999; 31: S3-8.
3. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672.
4. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
5. Fried MW, Shiffman ML, Reddy RK et al. Pegylated interferon alfa-2a in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study. Gastroenterology 2001; 120: A-55.
6. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
7. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
8. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis (2 with high-dose interferon alpha-2b. A multicenter study. Dig Dis Sci 1993; 38: 612-618.
9. Bekkering FC, Brouwer JT, Leroux-Roels G, Van Vlierberghe H, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol 1998; 28: 960-4.
10. Glue P, Fang JW, Rouzier-Panis R et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556-567.
11. Reichard O, Foberg U, Fryden A et al. High sustained response rate and clearance of viremia in chronic hepatitis (2 after treatment with interferon-alpha 2b for 60 weeks. Hepatology 1994; 19: 280-285.
12. Poynard T, Bedossa P, Chevallier M et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995; 332: 1457-1462.
13. Brouwer JT, Hansen BE, Schalm SW. Low relapse rate in chronic hepatitis C treated with 18 months Interferon-alfa and Ribavirin as compared to 6 months monotherapy. A BeNeLux study in 300 patients. Hepatology 2000; 32: 317A.
14. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000; 31(1): 211-218.
15. Brouwer JT, Nevens F, Kleter B et al. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. J Hepatol 1998; 28: 951-959.
16. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472.
17. Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 2001; 33: 419-423.
18. Bekkering FC, Neumann AU, Brouwer JT, Levi-Drummer RS, Schalm SW. Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study. BMC Gastroenterol 2001; 1: 14.
19. Lindsay KL, Trepo C, Heintges T et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
20. Ferenci P, Brunner H, Nachbaur K et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001; 34: 1006-1011.
21. Bjoro K, Bell H, Helium KB et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol 2002; 37: 226-232.
22. Carithers LJ, Zeuzem S, Manns MP et al. Multicenter, randomized, controlled trail comparing high dose daily induction interferon plus ribavirin versus standard interferon alfa-2b plus ribavirin. Hepatology 2000; 32(4): 317A.